About this Special Issue
In recent years, the pathogenesis of atopic dermatitis has become more clearly elucidated, and barrier dysfunction, type 2 inflammatory response, and itching are considered to be the three main pathophysiologic factors.
A number of new systemic and topical therapies, such as biologics and JAK inhibitors, are now available to improve these abnormalities.
However, various issues have arisen that need to be discussed, such as the characteristics of each drug, which patients it should be used in, and what side effects it may cause.
Furthermore, the development of highly effective drugs that can be used clinically in the future is also expected.
Please elucidate how the new systemic therapies and topical agents currently available should be used differently and effectively, and with what attention to detail they should be used in patients.
In addition, it is also requested that the results of basic research leading to the development of new therapeutic agents for atopic dermatitis.
Novel basic and clinical findings related to the pathogenesis of the three main pathologies of atopic dermatitis, i.e., barrier dysfunction, type 2 inflammatory response, and itching, are also desirable.
Characteristics, real world data, and side effects of novel systemic and topical therapies such as biologics and JAK inhibitors that suppress TH2 cytokines
• Novel biomarkers that can assess therapeutic efficacy
• Novel methods for physicians and patients to evaluate treatment efficacy
• Basic research results leading to the development of new treatment
• Research results aimed at elucidating new pathophysiology in barrier dysfunction, type 2 inflammatory response, and itching
A number of new systemic and topical therapies, such as biologics and JAK inhibitors, are now available to improve these abnormalities.
However, various issues have arisen that need to be discussed, such as the characteristics of each drug, which patients it should be used in, and what side effects it may cause.
Furthermore, the development of highly effective drugs that can be used clinically in the future is also expected.
Please elucidate how the new systemic therapies and topical agents currently available should be used differently and effectively, and with what attention to detail they should be used in patients.
In addition, it is also requested that the results of basic research leading to the development of new therapeutic agents for atopic dermatitis.
Novel basic and clinical findings related to the pathogenesis of the three main pathologies of atopic dermatitis, i.e., barrier dysfunction, type 2 inflammatory response, and itching, are also desirable.
Characteristics, real world data, and side effects of novel systemic and topical therapies such as biologics and JAK inhibitors that suppress TH2 cytokines
• Novel biomarkers that can assess therapeutic efficacy
• Novel methods for physicians and patients to evaluate treatment efficacy
• Basic research results leading to the development of new treatment
• Research results aimed at elucidating new pathophysiology in barrier dysfunction, type 2 inflammatory response, and itching
Keywords: Atopic dermatitis, New systemic therapy, Th2 cytokine, pruritus, Skin barrier disorders
